Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Abernethy Matt sold 2,311 Neurocrine Biosciences, Inc. shares (Form 4)
Traded Sep 11 to Sep 14, 2026 · Filed Sep 15, 2026
From Sep 11 to Sep 14, 2026, Abernethy Matt (Chief Financial Officer) sold 2,311 Neurocrine Biosciences, Inc. shares at US$157.20 for US$363K under a trading plan, leaving 42,808 shares. Filed Sep 15, 2026 (Form 4).
- Sold
- 2,311 shares
- Price
- US$157.20
- Value
- US$363K
- Holding after
- 42,808 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | Award | 5,020 | 47,828 | Direct | |
| Sep 11, 2026 | Common Stock | Shares withheld for tax | 2,709 | US$156.22 | 45,119 | Direct |
| Sep 14, 2026 | Common Stock | Sale | 2,311 | US$157.20 | 42,808 | Direct |